Benzinga | Nov 9, 2021 06:07PM EST

AbCellera Biologics Q3 EPS $(0.02) Beats $(0.03) Estimate, Sales $9.36M Up From $5.51M YoY

AbCellera Biologics (NASDAQ:ABCL) reported quarterly losses of $(0.02) per share which beat the analyst consensus estimate of $(0.03) by 33.33 percent. The company reported $9.36 million in sales this quarter. This is a 69.97 percent increase over sales of $5.51 million the same period last year.